HONG KONG, Dec. 17, 2024 — Great Bay Bio (GBB) successfully concluded the initial phase of its Series B funding round. This achievement follows a lead investment from a prominent strategic investment firm and its affiliate, Tiger Jade Pebble Accelerator. The funding also included participation from new investors, such as a Hong Kong-based family office and the Hong Kong Science and Technology Parks Venture Fund, along with continued backing from an existing global life sciences investor. These funds will support GBB’s AI-driven drug development platform and accelerate the global use of its innovative technologies. This represents substantial progress in transforming international biologics development.

GBB’s commercial activities are thriving, driven by technological advancements and market-focused solutions. In cell line development, GBB’s AlfaCell platform has assisted clients in obtaining clinical trial approvals from both China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). These cell lines have been used in various projects, with partners praising increased yields and reduced development times, particularly for multi-specific antibodies. Furthermore, GBB has improved its cell culture capabilities by establishing its own ISO 9001:2015-certified cell culture powder production facility, guaranteeing a reliable and high-quality supply chain. These accomplishments have solidified GBB’s position as a trusted partner for leading multinational corporations in life sciences, specialty chemicals, and pharmaceutical CDMO sectors, addressing the global need for faster and more efficient new product development.

Building on this, GBB recently introduced an integrated ecosystem solution, merging its advanced technological platforms into a streamlined workflow. This innovation allows clients to expedite drug development, from target identification to pre-clinical candidate (PCC) generation, in as little as eight months. Although GBB has only recently begun collaborations using this approach, preliminary findings are positive and demonstrate its potential to revolutionize the efficiency and speed of drug development, delivering significant value to global partners.

Kingsley Leung, GBB’s Co-founder and Chairman, stated: “GBB was established with a global perspective, and our measure of success has always been the development of globally distinct technologies. We are confident in our capacity to continue building an international presence, particularly across the U.S., Europe, and Asia-Pacific, where we see considerable growth opportunities. The robust support from our Series B investors reflects their confidence in our vision and reinforces our commitment to driving innovation that transforms the biopharmaceutical sector globally.”

Emmanuel Hui, CEO of Tiger Jade Pebble Accelerator, commented: “The most significant hurdles for applying AI in the biomedical field are scientific feedback and market viability. Innovators frequently lack certainty regarding the efficacy of their AI products until after extensive animal and human testing, and even then, the payment model remains unclear. GBB’s focused strengths in cell line, culture media, and bioprocessing differ from general AI drug discovery, allowing for immediate feedback, iteration, and client payment.”

About GBB

Great Bay Bio (GBB), located in HKSTP, is a biotechnology company that accelerates drug development using cutting-edge technologies like AI, big data analysis, and automation. GBB operates under the corporate vision of “Global Bioprocessing Made Simpler and More Efficient,” aiming to overcome the challenges of lengthy timelines, high costs, and low success rates in drug development, with a long-term goal of improving human life, health, and well-being.

GBB’s core team includes experts in medicine, synthetic biology, and artificial intelligence. The company operates a 3,000㎡ R&D laboratory and CMC platform, assisting clients in obtaining clinical trial approvals from China’s NMPA and the US FDA. GBB holds nearly 100 patents related to AI-driven drug development and has successfully commercialized several AI technology platforms. The company has forged long-term partnerships with leading domestic and international businesses.

GBB is ISO 9001:2015 certified, featured on the Forbes Asia 100 to Watch 2024 List, and has received numerous awards including “Deloitte Technology Rising Star Company,” “EY Entrepreneur Of The Year,” “15th Shenzhen Innovation & Entrepreneurship Competition,” “Gold Award for Hong Kong Global Innovation,” “Excellence in Process Innovation Award,” and “Excellence in Technology Adoption Award”. The company has also been accepted into the Hong Kong Science Park Elite Enterprise Program.

 

SOURCE Great Bay Bio Limited

“`